Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated inflammation

Yasuhiro Nakano, Tetsuya Matoba, Masaki Tokutome, Daiki Funamoto, Shunsuke Katsuki, Gentaro Ikeda, Kazuhiro Nagaoka, Ayako Ishikita, Kaku Nakano, Jun Ichiro Koga, Kenji Sunagawa, Kensuke Egashira

    Research output: Contribution to journalArticlepeer-review

    40 Citations (Scopus)

    Abstract

    Myocardial ischemia-reperfusion (IR) injury limits the therapeutic effect of early reperfusion therapy for acute myocardial infarction (AMI), in which the recruitment of inflammatory monocytes plays a causative role. Here we develop bioabsorbable poly-lactic/glycolic acid (PLGA) nanoparticles incorporating irbesartan, an angiotensin II type 1 receptor blocker with a peroxisome proliferator-activated receptor (PPAR)γ agonistic effect (irbesartan-NP). In a mouse model of IR injury, intravenous PLGA nanoparticles distribute to the IR myocardium and monocytes in the blood and in the IR heart. Single intravenous treatment at the time of reperfusion with irbesartan-NP (3.0 mg kg -1 irbesartan), but not with control nanoparticles or irbesartan solution (3.0 mg kg -1), inhibits the recruitment of inflammatory monocytes to the IR heart, and reduces the infarct size via PPARγ-dependent anti-inflammatory mechanisms, and ameliorates left ventricular remodeling 21 days after IR. Irbesartan-NP is a novel approach to treat myocardial IR injury in patients with AMI.

    Original languageEnglish
    Article number29601
    JournalScientific reports
    Volume6
    DOIs
    Publication statusPublished - Jul 11 2016

    All Science Journal Classification (ASJC) codes

    • General

    Fingerprint Dive into the research topics of 'Nanoparticle-mediated delivery of irbesartan induces cardioprotection from myocardial ischemia-reperfusion injury by antagonizing monocyte-mediated inflammation'. Together they form a unique fingerprint.

    Cite this